The GLP-1 drug class has upended the obesity treatment landscape. Where the previous generation of weight loss drugs could produce 5-8% body weight reduction, semaglutide averages 15-17% and tirzepatide pushes toward 20-22% — figures that were considered impossible without surgery five years ago.
Now a third generation of molecules is entering trials and limited clinical use. Here's an honest comparison of what's available and what's coming.
Understanding the Mechanisms
GLP-1 receptor agonism: GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It signals satiety, slows gastric emptying, and reduces appetite. All the medications in this class mimic or amplify GLP-1 signaling.
GIP receptor agonism: GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone. Tirzepatide adds GIP receptor agonism to GLP-1 agonism — the combination appears to produce additive or synergistic effects on weight loss.
Triple agonism (glucagon + GIP + GLP-1): The next frontier. Adding glucagon receptor agonism directly stimulates energy expenditure rather than just reducing intake. This is the mechanism behind retatrutide and some other pipeline molecules.
Semaglutide
Brand names: Ozempic (diabetes), Wegovy (weight loss) Compounded: Available through compounding pharmacies since 2022
Mechanism: GLP-1 receptor agonist (mono-agonist)
Dosing: Weekly subcutaneous injection. Titrated from 0.25mg to 2.4mg over approximately 16-20 weeks.
Weight loss results (STEP trials): - Average: 14.9% body weight reduction at 68 weeks vs. 2.4% placebo - Best responders: 20-25%+ reduction - About 35% of patients achieve ≥15% weight loss; about 10% achieve ≥20%
Cardiovascular data: The SELECT trial (2023) showed 20% reduction in major cardiovascular events in adults with obesity and CVD. Landmark finding.
Side effects: - Nausea, vomiting, constipation (most common; typically subside after titration) - Rare: pancreatitis, gallbladder disease - GI side effects typically most prominent in months 1-3
Availability: FDA-approved. Compounded semaglutide widely available; note that FDA removed semaglutide from shortage list in early 2025, which has complicated compounding availability. Some states still permit it; check current availability with your provider.
Cost (compounded): $200-350/month
Tirzepatide
Brand names: Mounjaro (diabetes), Zepbound (weight loss) Compounded: Available; note similar FDA shortage-list dynamics as semaglutide
Mechanism: Dual GLP-1 and GIP receptor agonist (dual agonist)
Dosing: Weekly subcutaneous injection. Titrated from 2.5mg to 15mg over approximately 20 weeks.
Weight loss results (SURMOUNT trials): - Average: 20.9% body weight reduction at 72 weeks vs. 3.1% placebo (at maximum 15mg dose) - Best responders: 30%+ reduction - About 57% achieve ≥15% weight loss; about 36% achieve ≥20%
vs. Semaglutide head-to-head (SURMOUNT-5 trial): Tirzepatide produced 47% greater weight loss than semaglutide in a direct comparison (20.2% vs. 13.7% at 72 weeks).
Cardiovascular data: SURPASS-CVOT for diabetes showed non-inferiority to dulaglutide; full cardiovascular outcomes trial for obesity ongoing.
Side effects: Similar to semaglutide (nausea, vomiting, constipation) but many patients report better GI tolerability despite greater efficacy. The GIP component may attenuate nausea.
Cost (compounded): $250-400/month
Bottom line vs. semaglutide: Tirzepatide consistently produces ~5-7% additional weight loss and appears better tolerated by many patients. For most patients choosing between the two, tirzepatide is the stronger option if cost difference is manageable.
Retatrutide (Next Generation)
Status: Phase 3 trials ongoing; not yet FDA-approved; available through some compounding pharmacies and research settings in limited quantities.
Mechanism: Triple agonist — GLP-1 + GIP + glucagon receptor
Adding glucagon receptor agonism is the key differentiator. Glucagon stimulates hepatic glucose production and directly increases energy expenditure (thermogenesis). The combination targets three separate mechanisms simultaneously.
Phase 2 results (NEJM, 2023): - Average weight loss: 24.2% at 48 weeks (maximum dose, 12mg) - 83% of participants lost at least 5% of body weight - 26% lost at least 30% — a number approaching bariatric surgery outcomes
Liver fat: Remarkable effect on hepatic steatosis (fatty liver disease) beyond weight loss alone — possibly due to the glucagon component's direct liver effects.
Side effects: Similar GI profile to semaglutide and tirzepatide. Some concern about glucagon-related effects (slight heart rate increase seen in early trials).
Phase 3 data expected: 2025-2026. FDA approval timeline: potentially 2027.
Current availability: Limited compounding access; not a mainstream prescribable option yet.
CagriSema and Combination Approaches
CagriSema (semaglutide + cagrilintide) combines a GLP-1 agonist with an amylin analog. Phase 3 data showing approximately 22.7% weight loss — competitive with tirzepatide.
Amylin: A pancreatic hormone that works differently than GLP-1, acting on brain circuits to reduce food intake through complementary mechanisms. Adding it to semaglutide produces synergistic effects.
This is the direction the field is moving: stacking multiple hormonal targets to address different aspects of appetite, energy expenditure, and metabolism.
Choosing Between Available Options
For most patients starting GLP-1 treatment in 2026:
Choose semaglutide if: - Cost is a primary concern - You have cardiovascular disease (SELECT trial benefit established) - Availability is reliable in your region
Choose tirzepatide if: - Maximizing weight loss is the priority - GI tolerability is a concern with semaglutide - The cost difference is manageable
Consider retatrutide/pipeline agents if: - You've plateau'd on semaglutide or tirzepatide - You have significant hepatic steatosis or metabolic complication - You're working with a physician who has access to clinical programs
What Isn't Different Between Them
All GLP-1 medications require the same fundamentals: - Adequate protein intake (1g+/lb/day) to preserve muscle - Resistance training to protect lean mass - Regular monitoring of body composition, not just scale weight - Long-term plan for maintenance — weight regain occurs when stopping
The medication choice is important but secondary to the protocol around it.
Frequently Asked Questions
Which GLP-1 medication causes the most weight loss?
In clinical trials, tirzepatide produces greater average weight loss than semaglutide (~21% vs ~15% body weight at maximum doses). Retatrutide shows even higher results (~24%) in early trials but isn't FDA-approved yet. Individual response varies significantly — some patients lose more on semaglutide than the average tirzepatide result.
Is tirzepatide worth the extra cost over semaglutide?
For most patients, the ~5-7% additional weight loss and potentially better GI tolerability make tirzepatide a reasonable upgrade if the cost difference is manageable. The SURMOUNT-5 head-to-head trial showed 47% greater weight loss with tirzepatide — not a small difference. If cost is primary, semaglutide still produces excellent results.
When will retatrutide be available?
Phase 3 trials are ongoing as of 2026. FDA approval is not expected until 2027 at the earliest. Limited compounding access exists but is not mainstream. Watch for Phase 3 data publication in 2025-2026 for a clearer picture of approval timeline.
Do GLP-1 medications work differently for different people?
Yes, significantly. About 10-15% of patients are 'super-responders' who lose 25%+ of body weight; another group sees modest results. Genetic factors, gut microbiome, baseline insulin resistance, and protocol adherence all influence response. If you plateau or don't respond adequately to one medication, the next-generation options may work better for you.
Get our free Body Composition Guide
Protein protocols, workout structure, sleep optimization, and the supplement stack that actually works.
Get our free Body Composition Guide →
